Paul Friedman, MD
Pulmonary Disease · Manasquan, NJNPI 1386646040
Payments from drug & device makers
Across 762 payments — averaging $76.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$49K
- AstraZeneca$3K
- Philips North America LLC$1K
- Regeneron Healthcare Solutions, Inc.$969
- Boehringer Ingelheim$935
- Sanofi$826
- plus $2K from 24 others
What the payments were for
- Speaking & faculty fees$44,80077%
- Travel & lodging$7111%
- Food & beverage$12,56922%
- Education$1950%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 242 | $49,146 |
| AstraZeneca | 111 | $3,139 |
| Philips North America LLC | 114 | $1,172 |
| Regeneron Healthcare Solutions, Inc. | 44 | $969 |
| Boehringer Ingelheim | 67 | $935 |
| Sanofi | 44 | $826 |
| Amgen | 23 | $417 |
| Mylan Specialty L.p. | 23 | $364 |
| United Therapeutics Corporation | 13 | $211 |
| Actelion Pharmaceuticals US, Inc. | 12 | $173 |
| Electromed, Inc. | 16 | $158 |
| Genentech USA, Inc. | 8 | $110 |
| Covis Pharma GmbH | 7 | $107 |
| Novartis | 4 | $66 |
| Insmed, Inc. | 4 | $62 |
| Sunovion Pharmaceuticals Inc. | 6 | $60 |
| Viatris Specialty LLC | 3 | $59 |
| Baxter Healthcare | 3 | $52 |
| Grifols USA, LLC | 3 | $51 |
| Jazz Pharmaceuticals Inc. | 3 | $41 |
| Teva Pharmaceuticals USA, Inc. | 2 | $24 |
| Harmony Biosciences LLC | 2 | $22 |
| Shionogi Inc | 1 | $18 |
| Verona Pharma, Inc. | 1 | $17 |
| Bayer | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Mallinckrodt Hospital Products Inc. | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Optinose US, Inc. | 1 | $12 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$38,529
- ANORO$3,708
- ANORO ELLIPTA$3,600
- TEZSPIRE$1,201
- FASENRA$974
- AIRSUPRA$557
- DUPIXENT$517
- BEVESPI AEROSPHERE$432
- BREZTRI$412
- NUCALA$372
- OFEV$124
How this compares
$58,274 in reported general payments places this provider in the 90th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 918 | $762,620 |
| Breo ElliptaFluticasone/Vilanterol | 292 | $149,382 |
| EsbrietPirfenidone | 14 | $146,409 |
| Dupixent PenDupilumab | 28 | $135,759 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 144 | $106,710 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 127 | $98,637 |
| Dupixent SyringeDupilumab | 19 | $98,088 |
| Bosentan | 16 | $74,340 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 98 | $48,735 |
| Spiriva RespimatTiotropium Bromide | 57 | $42,603 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 220 | $29,880 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 623 | $27,583 |
| EliquisApixaban | 27 | $17,512 |
| Spiriva HandihalerTiotropium Bromide | 23 | $17,415 |
| Incruse ElliptaUmeclidinium Bromide | 40 | $17,042 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $49,146 | $987,3511,377 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $935 | $155,394201 claims |
| Genentech USA, Inc.Esbriet | $110 | $146,40914 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $3,139 | $118,734171 claims |
| Actelion Pharmaceuticals US, Inc.Bosentan | $173 | $74,34016 claims |
| PfizerEliquis | $12 | $17,51227 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $24 | $8,25419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in Manasquan
- Jeffrey MiskoffManasquan$228K
- Reynold PanettieriNew Brunswick$2.5M
- Vinay SikandToms River$1.8M
- Stanley FielMorristown$1.3M
- Joseph HoffmanPark Ridge$1.1M
- Robert SussmanSummit$645K
- Ronaldo GoHackensack$563K
- Deborah GossHackensack$558K
- Sabina HussainNew Brunswick$555K
- Manuel CunananMillville$489K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.